Skip to main content
Erschienen in: Journal of Neural Transmission 11/2011

01.11.2011 | Dementias - Original Article

The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer’s disease in rats

verfasst von: Ana Carolina Tramontina, Krista Minéia Wartchow, Letícia Rodrigues, Regina Biasibetti, André Quincozes-Santos, Larissa Bobermin, Francine Tramontina, Carlos-Alberto Gonçalves

Erschienen in: Journal of Neural Transmission | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

Astrocytes play a fundamental role in glutamate metabolism by regulating the extracellular levels of glutamate and intracellular levels of glutamine. They also participate in antioxidant defenses, due to the synthesis of glutathione, coupled to glutamate metabolism. Although the cause of Alzheimer’s disease (AD) remains elusive, some changes in neurochemical parameters, such as glutamate uptake, glutamine synthetase activity and glutathione have been investigated in this disease. A possible neuroprotective effect of two statins, simvastatin and pravastatin (administered p.o.), was evaluated using a model of dementia, based on the intracerebroventricular (ICV) administration of streptozotocin (STZ), and astrocyte parameters were determined. We confirmed a cognitive deficit in rats submitted to ICV-STZ, and a prevention of this deficit by statin administration. Moreover, both statins were able to prevent the decrease in glutathione content and glutamine synthetase activity in this model of AD. Interestingly, simvastatin increased per se glutamate uptake activity, while both statins increased glutamine synthetase activity per se. These results support the idea that these drugs could be effective for the prevention of alterations observed in the STZ dementia model and may contribute to reduce the cognitive impairment and brain damage observed in AD patients.
Literatur
Zurück zum Zitat Adamson P, Greenwood J (2003) How do statins control neuroinflammation? Inflamm Res 52:399–403PubMedCrossRef Adamson P, Greenwood J (2003) How do statins control neuroinflammation? Inflamm Res 52:399–403PubMedCrossRef
Zurück zum Zitat Bandoh T, Mitani H, Niihashi M, Kusumi Y, Kimura M, Ishikawa J, Totsuka T, Sakurai I, Hayashi S (2000) Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol 35:136–144PubMedCrossRef Bandoh T, Mitani H, Niihashi M, Kusumi Y, Kimura M, Ishikawa J, Totsuka T, Sakurai I, Hayashi S (2000) Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol 35:136–144PubMedCrossRef
Zurück zum Zitat Barone E, Cenini G, Di Domenico F, Martin S, Sultana R, Mancuso C, Murphy MP, Head E, Butterfield DA (2011) Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res 63:172–180PubMedCrossRef Barone E, Cenini G, Di Domenico F, Martin S, Sultana R, Mancuso C, Murphy MP, Head E, Butterfield DA (2011) Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res 63:172–180PubMedCrossRef
Zurück zum Zitat Bosel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, Megow D, Dirnagl U, Hortnagl H, Fink KB, Endres M (2005) Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 92:1386–1398PubMedCrossRef Bosel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, Megow D, Dirnagl U, Hortnagl H, Fink KB, Endres M (2005) Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 92:1386–1398PubMedCrossRef
Zurück zum Zitat Browne RW, Armstrong D (1998) Reduced glutathione and glutathione disulfide. Methods Mol Biol 108:347–352PubMed Browne RW, Armstrong D (1998) Reduced glutathione and glutathione disulfide. Methods Mol Biol 108:347–352PubMed
Zurück zum Zitat Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R, Bredesen DE (2010) In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 48:136–144PubMedCrossRef Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R, Bredesen DE (2010) In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 48:136–144PubMedCrossRef
Zurück zum Zitat Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Bona DD, Duro G, Lio D, Matranga D, Pellicano M, Risso C, Scapagnini G, Vasto S (2010) Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res 13:301–313PubMedCrossRef Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Bona DD, Duro G, Lio D, Matranga D, Pellicano M, Risso C, Scapagnini G, Vasto S (2010) Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res 13:301–313PubMedCrossRef
Zurück zum Zitat Canevari L, Clark JB (2007) Alzheimer’s disease and cholesterol: the fat connection. Neurochem Res 32:739–750PubMedCrossRef Canevari L, Clark JB (2007) Alzheimer’s disease and cholesterol: the fat connection. Neurochem Res 32:739–750PubMedCrossRef
Zurück zum Zitat dos Santos AQ, Nardin P, Funchal C, de Almeida LM, Jacques-Silva MC, Wofchuk ST, Goncalves CA, Gottfried C (2006) Resveratrol increases glutamate uptake and glutamine synthetase activity in C6 glioma cells. Arch Biochem Biophys 453:161–167PubMedCrossRef dos Santos AQ, Nardin P, Funchal C, de Almeida LM, Jacques-Silva MC, Wofchuk ST, Goncalves CA, Gottfried C (2006) Resveratrol increases glutamate uptake and glutamine synthetase activity in C6 glioma cells. Arch Biochem Biophys 453:161–167PubMedCrossRef
Zurück zum Zitat Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856–5861PubMedCrossRef Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856–5861PubMedCrossRef
Zurück zum Zitat Gottfried C, Tramontina F, Goncalves D, Goncalves CA, Moriguchi E, Dias RD, Wofchuk ST, Souza DO (2002) Glutamate uptake in cultured astrocytes depends on age: a study about the effect of guanosine and the sensitivity to oxidative stress induced by H(2)O(2). Mech Ageing Dev 123:1333–1340PubMedCrossRef Gottfried C, Tramontina F, Goncalves D, Goncalves CA, Moriguchi E, Dias RD, Wofchuk ST, Souza DO (2002) Glutamate uptake in cultured astrocytes depends on age: a study about the effect of guanosine and the sensitivity to oxidative stress induced by H(2)O(2). Mech Ageing Dev 123:1333–1340PubMedCrossRef
Zurück zum Zitat Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101:757–770PubMedCrossRef Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101:757–770PubMedCrossRef
Zurück zum Zitat Hoglund K, Blennow K (2007) Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer’s disease. CNS Drugs 21:449–462PubMedCrossRef Hoglund K, Blennow K (2007) Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer’s disease. CNS Drugs 21:449–462PubMedCrossRef
Zurück zum Zitat Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356:1627–1631PubMedCrossRef Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356:1627–1631PubMedCrossRef
Zurück zum Zitat Kandiah N, Feldman HH (2009) Therapeutic potential of statins in Alzheimer’s disease. J Neurol Sci 283:230–234PubMedCrossRef Kandiah N, Feldman HH (2009) Therapeutic potential of statins in Alzheimer’s disease. J Neurol Sci 283:230–234PubMedCrossRef
Zurück zum Zitat Kirsch C, Eckert GP, Mueller WE (2003) Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65:843–856PubMedCrossRef Kirsch C, Eckert GP, Mueller WE (2003) Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65:843–856PubMedCrossRef
Zurück zum Zitat Kuipers HF, van den Elsen PJ (2007) Immunomodulation by statins: inhibition of cholesterol vs. isoprenoid biosynthesis. Biomed Pharmacother 61:400–407PubMedCrossRef Kuipers HF, van den Elsen PJ (2007) Immunomodulation by statins: inhibition of cholesterol vs. isoprenoid biosynthesis. Biomed Pharmacother 61:400–407PubMedCrossRef
Zurück zum Zitat Kurata T, Miyazaki K, Kozuki M, Panin VL, Morimoto N, Ohta Y, Nagai M, Ikeda Y, Matsuura T, Abe K (2011) Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res 1371:161–170PubMedCrossRef Kurata T, Miyazaki K, Kozuki M, Panin VL, Morimoto N, Ohta Y, Nagai M, Ikeda Y, Matsuura T, Abe K (2011) Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res 1371:161–170PubMedCrossRef
Zurück zum Zitat Lannert H, Hoyer S (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112:1199–1208PubMedCrossRef Lannert H, Hoyer S (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112:1199–1208PubMedCrossRef
Zurück zum Zitat Li L, Cao D, Kim H, Lester R, Fukuchi K (2006) Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 60:729–739PubMedCrossRef Li L, Cao D, Kim H, Lester R, Fukuchi K (2006) Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 60:729–739PubMedCrossRef
Zurück zum Zitat Li B, Mahmood A, Lu D, Wu H, Xiong Y, Qu C, Chopp M (2009) Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. Neurosurgery 65:179–185; discussion 185–176 Li B, Mahmood A, Lu D, Wu H, Xiong Y, Qu C, Chopp M (2009) Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. Neurosurgery 65:179–185; discussion 185–176
Zurück zum Zitat Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89–118PubMedCrossRef Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89–118PubMedCrossRef
Zurück zum Zitat Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMed Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMed
Zurück zum Zitat Maccioni RB, Munoz JP, Barbeito L (2001) The molecular bases of Alzheimer’s disease and other neurodegenerative disorders. Arch Med Res 32:367–381PubMedCrossRef Maccioni RB, Munoz JP, Barbeito L (2001) The molecular bases of Alzheimer’s disease and other neurodegenerative disorders. Arch Med Res 32:367–381PubMedCrossRef
Zurück zum Zitat Markesbery WR, Carney JM (1999) Oxidative alterations in Alzheimer’s disease. Brain Pathol 9:133–146PubMedCrossRef Markesbery WR, Carney JM (1999) Oxidative alterations in Alzheimer’s disease. Brain Pathol 9:133–146PubMedCrossRef
Zurück zum Zitat Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW, Mullan MJ (2001) Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J Neuropathol Exp Neurol 60:778–785PubMed Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW, Mullan MJ (2001) Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J Neuropathol Exp Neurol 60:778–785PubMed
Zurück zum Zitat Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47–60PubMedCrossRef Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47–60PubMedCrossRef
Zurück zum Zitat Mrak RE, Griffinbc WS (2001) The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease. Neurobiol Aging 22:915–922PubMedCrossRef Mrak RE, Griffinbc WS (2001) The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease. Neurobiol Aging 22:915–922PubMedCrossRef
Zurück zum Zitat Nagay Hernandez S, Flores Molina JJ, Ilarraza Lomeli H, Martinez Sanchez C, del Valle Mondragon L, Tenorio Lopez FA, Pastelin Hernandez G (2008) Influence of rosuvastatin in endothelial function and oxidative stress, in patients with acute coronary syndrome. Arch Cardiol Mex 78:379–383PubMed Nagay Hernandez S, Flores Molina JJ, Ilarraza Lomeli H, Martinez Sanchez C, del Valle Mondragon L, Tenorio Lopez FA, Pastelin Hernandez G (2008) Influence of rosuvastatin in endothelial function and oxidative stress, in patients with acute coronary syndrome. Arch Cardiol Mex 78:379–383PubMed
Zurück zum Zitat Pasquier F, Boulogne A, Leys D, Fontaine P (2006) Diabetes mellitus and dementia. Diabetes Metab 32:403–414PubMedCrossRef Pasquier F, Boulogne A, Leys D, Fontaine P (2006) Diabetes mellitus and dementia. Diabetes Metab 32:403–414PubMedCrossRef
Zurück zum Zitat Paxinos (1997) The Rat Nervous System. Academic Press Paxinos (1997) The Rat Nervous System. Academic Press
Zurück zum Zitat Piermartiri TC, Figueiredo CP, Rial D, Duarte FS, Bezerra SC, Mancini G, de Bem AF, Prediger RD, Tasca CI (2010) Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1–40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp Neurol 226:274–284PubMedCrossRef Piermartiri TC, Figueiredo CP, Rial D, Duarte FS, Bezerra SC, Mancini G, de Bem AF, Prediger RD, Tasca CI (2010) Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1–40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp Neurol 226:274–284PubMedCrossRef
Zurück zum Zitat Ramirez C, Tercero I, Pineda A, Burgos JS (2011) Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. J Alzheimers Dis 24:161–174PubMed Ramirez C, Tercero I, Pineda A, Burgos JS (2011) Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. J Alzheimers Dis 24:161–174PubMed
Zurück zum Zitat Robinson SR (2001) Changes in the cellular distribution of glutamine synthetase in Alzheimer’s disease. J Neurosci Res 66:972–980PubMedCrossRef Robinson SR (2001) Changes in the cellular distribution of glutamine synthetase in Alzheimer’s disease. J Neurosci Res 66:972–980PubMedCrossRef
Zurück zum Zitat Rodrigues L, Biasibetti R, Swarowsky A, Leite MC, Quincozes-Santos A, Quilfeldt JA, Achaval M, Goncalves CA (2009) Hippocampal alterations in rats submitted to streptozotocin-induced dementia model are prevented by aminoguanidine. J Alzheimers Dis 17:193–202PubMed Rodrigues L, Biasibetti R, Swarowsky A, Leite MC, Quincozes-Santos A, Quilfeldt JA, Achaval M, Goncalves CA (2009) Hippocampal alterations in rats submitted to streptozotocin-induced dementia model are prevented by aminoguanidine. J Alzheimers Dis 17:193–202PubMed
Zurück zum Zitat Saheki A, Terasaki T, Tamai I, Tsuji A (1994) In vivo and in vitro blood–brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 11:305–311PubMedCrossRef Saheki A, Terasaki T, Tamai I, Tsuji A (1994) In vivo and in vitro blood–brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 11:305–311PubMedCrossRef
Zurück zum Zitat Saxena G, Singh SP, Agrawal R, Nath C (2008) Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharmacol 581:283–289PubMedCrossRef Saxena G, Singh SP, Agrawal R, Nath C (2008) Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharmacol 581:283–289PubMedCrossRef
Zurück zum Zitat Schonbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109:II18– II26 Schonbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109:II18– II26
Zurück zum Zitat Sharma M, Gupta YK (2001) Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci 68:1021–1029PubMedCrossRef Sharma M, Gupta YK (2001) Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci 68:1021–1029PubMedCrossRef
Zurück zum Zitat Sharma M, Gupta YK (2002) Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 71:2489–2498PubMedCrossRef Sharma M, Gupta YK (2002) Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 71:2489–2498PubMedCrossRef
Zurück zum Zitat Sharma B, Singh N, Singh M (2008) Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer’s disease by pitavastatin and donepezil. J Psychopharmacol 22:162–171PubMedCrossRef Sharma B, Singh N, Singh M (2008) Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer’s disease by pitavastatin and donepezil. J Psychopharmacol 22:162–171PubMedCrossRef
Zurück zum Zitat Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS (2010) Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood–brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 23:307–318 Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS (2010) Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood–brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 23:307–318
Zurück zum Zitat Silva MC, Rocha J, Pires CS, Ribeiro LC, Brolese G, Leite MC, Almeida LM, Tramontina F, Ziegler DR, Goncalves CA (2005) Transitory gliosis in the CA3 hippocampal region in rats fed on a ketogenic diet. Nutr Neurosci 8:259–264PubMedCrossRef Silva MC, Rocha J, Pires CS, Ribeiro LC, Brolese G, Leite MC, Almeida LM, Tramontina F, Ziegler DR, Goncalves CA (2005) Transitory gliosis in the CA3 hippocampal region in rats fed on a ketogenic diet. Nutr Neurosci 8:259–264PubMedCrossRef
Zurück zum Zitat Silvestrelli G, Lanari A, Parnetti L, Tomassoni D, Amenta F (2006) Treatment of Alzheimer’s disease: from pharmacology to a better understanding of disease pathophysiology. Mech Ageing Dev 127:148–157PubMedCrossRef Silvestrelli G, Lanari A, Parnetti L, Tomassoni D, Amenta F (2006) Treatment of Alzheimer’s disease: from pharmacology to a better understanding of disease pathophysiology. Mech Ageing Dev 127:148–157PubMedCrossRef
Zurück zum Zitat Stefani M, Liguri G (2009) Cholesterol in Alzheimer’s disease: unresolved questions. Curr Alzheimer Res 6:15–29PubMedCrossRef Stefani M, Liguri G (2009) Cholesterol in Alzheimer’s disease: unresolved questions. Curr Alzheimer Res 6:15–29PubMedCrossRef
Zurück zum Zitat Terwel D, Prickaerts J, Meng F, Jolles J (1995) Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine. Eur J Pharmacol 287:65–71PubMedCrossRef Terwel D, Prickaerts J, Meng F, Jolles J (1995) Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine. Eur J Pharmacol 287:65–71PubMedCrossRef
Zurück zum Zitat Thomazi AP, Godinho GF, Rodrigues JM, Schwalm FD, Frizzo ME, Moriguchi E, Souza DO, Wofchuk ST (2004) Ontogenetic profile of glutamate uptake in brain structures slices from rats: sensitivity to guanosine. Mech Ageing Dev 125:475–481PubMedCrossRef Thomazi AP, Godinho GF, Rodrigues JM, Schwalm FD, Frizzo ME, Moriguchi E, Souza DO, Wofchuk ST (2004) Ontogenetic profile of glutamate uptake in brain structures slices from rats: sensitivity to guanosine. Mech Ageing Dev 125:475–481PubMedCrossRef
Zurück zum Zitat Vaughan CJ, Delanty N (1999) Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30:1969–1973PubMedCrossRef Vaughan CJ, Delanty N (1999) Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30:1969–1973PubMedCrossRef
Zurück zum Zitat Weinstock M, Shoham S (2004) Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J Neural Transm 111:347–366PubMedCrossRef Weinstock M, Shoham S (2004) Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J Neural Transm 111:347–366PubMedCrossRef
Zurück zum Zitat M. Weinstock SS (2004) Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J Nerural Transmission M. Weinstock SS (2004) Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J Nerural Transmission
Zurück zum Zitat Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med 5:20PubMedCrossRef Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med 5:20PubMedCrossRef
Zurück zum Zitat Yoshida M (2003) Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb 10:140–144PubMedCrossRef Yoshida M (2003) Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb 10:140–144PubMedCrossRef
Zurück zum Zitat Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T (2003) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23:11104–11111PubMed Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T (2003) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23:11104–11111PubMed
Zurück zum Zitat Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B, Nitsch R, Hartung HP (2007) Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci 28:342–349PubMedCrossRef Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B, Nitsch R, Hartung HP (2007) Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci 28:342–349PubMedCrossRef
Metadaten
Titel
The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer’s disease in rats
verfasst von
Ana Carolina Tramontina
Krista Minéia Wartchow
Letícia Rodrigues
Regina Biasibetti
André Quincozes-Santos
Larissa Bobermin
Francine Tramontina
Carlos-Alberto Gonçalves
Publikationsdatum
01.11.2011
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 11/2011
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-011-0680-z

Weitere Artikel der Ausgabe 11/2011

Journal of Neural Transmission 11/2011 Zur Ausgabe

Basic Neurosciences, Genetics and Immunology - Original Article

Valeriana officinalis ameliorates vacuous chewing movements induced by reserpine in rats

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.